Cargando…
Ventricular arrhythmia risk due to chloroquine / hydroxychloroquine treatment for COVID-19: Should it be given
Autor principal: | Malviya, Amit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184982/ https://www.ncbi.nlm.nih.gov/pubmed/32534688 http://dx.doi.org/10.1016/j.ihj.2020.04.006 |
Ejemplares similares
-
Chloroquine and hydroxychloroquine for COVID-19: time to close the chapter
por: Gupta, Anunay, et al.
Publicado: (2020) -
Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19
por: Gevers, S., et al.
Publicado: (2020) -
Antimalarials (chloroquine and hydroxychloroquine) in the COVID-19 pandemic()
por: Jáuregui, Edwin
Publicado: (2021) -
Nephrotoxicity of Chloroquine and Hydroxychloroquine in COVID-19 Patients
por: Mahmoudi, Javad, et al.
Publicado: (2021) -
Hydroxychloroquine and chloroquine for COVID-19: psychiatric aspects of
patient safety considerations
por: Biswas, Partha Sarathi, et al.
Publicado: (2020)